Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Accumulated Expenses (2017 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Accumulated Expenses for 11 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 246.45% to $7.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 246.45% increase, with the full-year FY2025 number at $7.2 million, up 246.45% from a year prior.
  • Other Accumulated Expenses was $7.2 million for Q4 2025 at Intellia Therapeutics, up from $5.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $32.7 million in Q4 2022 to a low of $2.1 million in Q4 2024.
  • A 5-year average of $16.3 million and a median of $19.8 million in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 2752.56% in 2021, then crashed 92.44% in 2024.
  • Intellia Therapeutics' Other Accumulated Expenses stood at $2.9 million in 2021, then skyrocketed by 1038.42% to $32.7 million in 2022, then dropped by 16.13% to $27.4 million in 2023, then plummeted by 92.44% to $2.1 million in 2024, then skyrocketed by 246.45% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Other Accumulated Expenses are $7.2 million (Q4 2025), $5.6 million (Q3 2025), and $3.4 million (Q2 2025).